CLDF Title
Home | Contact Us | Bookmark
  HBV   HCC   HCV   HE   NASH   PBC   OTHER
About CLDF Centers of Educational Expertise  
Webcasts Slide Library Abstract Library Conference Highlights
 
NASH | Abstract Library
Abstract Library
 
The summaries are free for public use. The Chronic Liver Disease Foundation will continue to add and archive summaries of articles deemed relevant to CLDF by the Board of Trustees and its Advisors.
  1. Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis
    Oseini AM1, Cole BK2, Issa D3, Feaver RE2, Sanyal AJ3,4. Hepatol Int. 2018 Jan 3. doi: 10.1007/s12072-017-9838-6. [Epub ahead of print]


  2. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation
    Younossi ZM1,2. Liver Transpl. 2018 Feb;24(2):166-170. doi: 10.1002/lt.25003.


  3. Vitamin E as a Treatment for Nonalcoholic Fatty Liver Disease: Reality or Myth?
    El Hadi H1, Vettor R2, Rossato M3. Antioxidants (Basel). 2018 Jan 16;7(1). pii: E12. doi: 10.3390/antiox7010012.


  4. Silymarin: An option to treat non-alcoholic fatty liver disease
    Colica C1, Boccuto L2, Abenavoli L3. World J Gastroenterol. 2017 Dec 21;23(47):8437-8438. doi: 10.3748/wjg.v23.i47.8437.


  5. Predictors of Non-Alcoholic Liver Disease in Ethnically Diverse Overweight Children and Adolescents
    Botero P1. Curr Pediatr Rev. 2018 Jan 23. doi: 10.2174/1573396314666180124101521. [Epub ahead of print]


  6. Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease
    Baffy G1. Dig Dis Sci. 2018 Jan 22. doi: 10.1007/s10620-017-4903-5. [Epub ahead of print]


  7. Liver transplantation for non-alcoholic fatty liver disease
    Germani G1, Becchetti C2. Minerva Gastroenterol Dietol. 2017 Dec 15. doi: 10.23736/S1121-421X.17.02467-9. [Epub ahead of print]


  8. Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety
    Mills EP1, Brown KPD2, Smith JD3, Vang PW2, Trotta K2. Ther Adv Endocrinol Metab. 2018 Jan;9(1):15-28. doi: 10.1177/2042018817741852. Epub 2017 Dec 7.


  9. Pediatric Nonalcoholic Fatty Liver Disease: Current Thinking
    Nobili V1,2, Socha P3. J Pediatr Gastroenterol Nutr. 2018 Feb;66(2):188-192. doi: 10.1097/MPG.0000000000001823.


  10. Non-invasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials
    Caussy C1,2, Reeder SB3, Sirlin CB4, Loomba R1,5,6. Hepatology. 2018 Jan 21. doi: 10.1002/hep.29797. [Epub ahead of print]


  11. New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fattyliver disease
    Tada T1, Kumada T1, Toyoda H1, Saibara T2, Ono M2, Kage M3. Biomarkers. 2018 Jan 19:1-7. doi: 10.1080/1354750X.2018.1425915. [Epub ahead of print]


  12. Association between obstructive sleep apnea and non-alcoholic fatty liver disease: a systematic review and meta-analysis
    Jin S1, Jiang S2, Hu A3,4. Sleep Breath. 2018 Jan 15. doi: 10.1007/s11325-018-1625-7. [Epub ahead of print]


  13. Nonalcoholic steatohepatitis: the new frontier for liver transplantation
    Bzowej NH1. Curr Opin Organ Transplant. 2018 Jan 19. doi: 10.1097/MOT.0000000000000502. [Epub ahead of print]


  14. Obese children with fatty liver: Between reality and disease mongering
    Ranucci G1, Spagnuolo MI1, Iorio R2. World J Gastroenterol. 2017 Dec 21;23(47):8277-8282. doi: 10.3748/wjg.v23.i47.8277.


  15. Low Circulating Levels of Neurotensin in Women with Nonalcoholic Fatty LiverDisease Associated with Severe Obesity
    Auguet T1,2, Aragonès G1, Berlanga A1, Martínez S3, Sabench F4, Aguilar C1, Villar B2, Sirvent JJ3, Del Castillo D4, Richart C1,2. Obesity (Silver Spring). 2018 Feb;26(2):274-278. doi: 10.1002/oby.22058. Epub 2017 Dec 25.


  16. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease
    Perumpail BJ1, Khan MA2, Yoo ER3, Cholankeril G4, Kim D4, Ahmed A5. World J Gastroenterol. 2017 Dec 21;23(47):8263-8276. doi: 10.3748/wjg.v23.i47.8263.


  17. An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis
    Davidson MB1, Pan D2. Diabetes Res Clin Pract. 2017 Nov 13;135:102-110. doi: 10.1016/j.diabres.2017.11.002. [Epub ahead of print]


  18. Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
    Tully DC1,2, Rucker PV1, Chianelli D1, Williams J1, Vidal A1, Alper PB1, Mutnick D1, Bursulaya B1, Schmeits J1, Wu X1, Bao D1, Zoll J1, Kim Y1, Groessl T1, McNamara P1, Seidel HM1, Molteni V1, Liu B1, Phimister A2, Joseph SB1, Laffitte B1. J Med Chem. 2017 Dec 28;60(24):9960-9973. doi: 10.1021/acs.jmedchem.7b00907. Epub 2017 Dec 8.


  19. Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis
    Hameed B1, Terrault NA1, Gill RM1, Loomba R2, Chalasani N3, Hoofnagle JH4, Van Natta ML5; NASH CRN. Aliment Pharmacol Ther. 2018 Jan 14. doi: 10.1111/apt.14492. [Epub ahead of print]


  20. Liver transplantation for NASH-related hepatocellular carcinoma versus non-NASH etiologies of hepatocellular carcinoma
    Sadler EM1,1, Mehta N1, Bhat M1,1, Ghanekar A1,1, Greig PD1,1, Grant DR1,1, Yao F1, Sapisochin G1,1. Transplantation. 2018 Jan 10. doi: 10.1097/TP.0000000000002043. [Epub ahead of print]


  21. Alcoholic hepatitis versus non-alcoholic steatohepatitis: Levels of expression of some proteins involved in tumorigenesis
    Nguyen L1, Masouminia M2, Mendoza A2, Samadzadeh S2, Tillman B2, Morgan T3, French B2, French S2. Exp Mol Pathol. 2018 Jan 4;104(1):45-49. doi: 10.1016/j.yexmp.2017.12.007. [Epub ahead of print]


  22. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma
    Said A1, Ghufran A2. World J Clin Oncol. 2017 Dec 10;8(6):429-436. doi: 10.5306/wjco.v8.i6.429.


  23. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus
    Targher G1, Lonardo A2, Byrne CD3,4. Nat Rev Endocrinol. 2018 Feb;14(2):99-114. doi: 10.1038/nrendo.2017.173. Epub 2017 Dec 29.


  24. Prevention of Tamoxifen-related Nonalcoholic Fatty Liver Disease in Breast Cancer Patients
    Chang HT1, Pan HJ2, Lee CH3. Clin Breast Cancer. 2017 Nov 23. pii: S1526-8209(17)30357-9. doi: 10.1016/j.clbc.2017.11.010. [Epub ahead of print]


  25. Impact of steatosis and inflammation definitions on the performance of NASHtests
    Poynard T1,2,3, Munteanu M4, Charlotte F1,2, Perazzo H1,2,3, Ngo Y4, Deckmyn O4, Pais R1,2,3, Mathurin P5, Ratziu V1,2,3; for the FLIP consortium, the FibroFrance-CPAM group; and the FibroFrance-Obese group. Eur J Gastroenterol Hepatol. 2017 Dec 26. doi: 10.1097/MEG.0000000000001033. [Epub ahead of print]


  26. Current and future pharmacological therapies for NAFLD/NASH
    Sumida Y1, Yoneda M2. J Gastroenterol. 2017 Dec 16. doi: 10.1007/s00535-017-1415-1. [Epub ahead of print]


  27. Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid
    Yoo W1, Gjuka D1, Stevenson HL2, Song X3, Shen H1, Yoo SY4, Wang J4, Fallon M5, Ioannou GN6, Harrison SA7, Beretta L1. PLoS One. 2017 Dec 15;12(12):e0189965. doi: 10.1371/journal.pone.0189965. eCollection 2017.


  28. Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes
    Simeone JC1, Bae JP2, Hoogwerf BJ3, Li Q1, Haupt A3, Ali AK4, Boardman MK3, Nordstrom BL1. Clin Epidemiol. 2017 Dec 14;9:679-688. doi: 10.2147/CLEP.S144368. eCollection 2017.


  29. Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease
    Eddowes PJ1, McDonald N2, Davies N1, Semple SIK2, Kendall TJ2, Hodson J1, Newsome PN1, Flintham RB1, Wesolowski R1, Blake L1, Duarte RV3, Kelly CJ4, Herlihy AH4, Kelly MD4, Olliff SP1, Hübscher SG1, Fallowfield JA2, Hirschfield GM1. Aliment Pharmacol Ther. 2017 Dec 22. doi: 10.1111/apt.14469. [Epub ahead of print]


  30. Relationship between Hypothyroidism and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis
    He W1, An X2, Li L2, Shao X2, Li Q2, Yao Q2, Zhang JA3. Front Endocrinol (Lausanne). 2017 Nov 29;8:335. doi: 10.3389/fendo.2017.00335. eCollection 2017.


  31. Association between nonalcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study
    Lee SB1, Park GM2, Lee JY3, Lee BU1, Park JH1, Kim BG1, Jung SW1, Jeong ID1, Bang SJ1, Shin JW1, Park NH1, Yang DH4, Kang JW4, Lim TH4, Kim HK5, Choe J5, Lee HC6. J Hepatol. 2017 Dec 20. pii: S0168-8278(17)32527-8. doi: 10.1016/j.jhep.2017.12.012. [Epub ahead of print]


  32. Non-Alcoholic Fatty Liver Disease and HIV/AIDS: A New Way of Modulation of Cardiovascular Risk
    Ahmed MH1, Husain NE2, Malik A3, Woodward C4, Mital D4. AIDS Rev. 2017 Oct-Dec;19(4):190-197.


  33. Clinical relevance of liver histopathology and different histological classifications of NASH in adults
    Nascimbeni F1,2, Ballestri S3, Machado MV4, Mantovani A5, Cortez-Pinto H4, Targher G5, Lonardo A1. Expert Rev Gastroenterol Hepatol. 2017 Dec 26:1-17. doi: 10.1080/17474124.2018.1415756. [Epub ahead of print]


  34. Hepatitis, Nonalcoholic Steatohepatitis
    Sharma B1, John S2.


  35. Liver Transplantation in Cryptogenic Cirrhosis: Outcome comparisons between NASH, Alcoholic and AIH cirrhosis
    Thuluvath PJ1, Hanish S, Savva Y. Transplantation. 2017 Dec 5. doi: 10.1097/TP.0000000000002030. [Epub ahead of print]


  36. Non-alcoholic Fatty Liver Disease: A Clinical Update
    Pappachan JM1, Babu S2, Krishnan B3, Ravindran NC4. J Clin Transl Hepatol. 2017 Dec 28;5(4):384-393. doi: 10.14218/JCTH.2017.00013. Epub 2017 Jul 26.


  37. Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease
    Rowe IA1. Lancet Gastroenterol Hepatol. 2018 Jan;3(1):66-72. doi: 10.1016/S2468-1253(17)30142-5.


  38. Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279?013 individuals
    Lauridsen BK1,2, Stender S1,2, Kristensen TS2,3, Kofoed KF2,4, Køber L2,4, Nordestgaard BG2,5,6,7, Tybjærg-Hansen A1,2,5,7. Eur Heart J. 2017 Dec 8. doi: 10.1093/eurheartj/ehx662. [Epub ahead of print]


  39. Effect of aerobic exercise and diet on liver fat in pre-diabetic patients with non-alcoholic-fatty-liver-disease: A randomized controlled trial
    Cheng S1,2,3, Ge J4, Zhao C5, Le S6, Yang Y6, Ke D5, Wu N6, Tan X6,7, Zhang X6, Du X4, Sun J8, Wang R5, Shi Y9, Borra RJH10,11, Parkkola R10, Wiklund P7,12,13, Lu D14. Sci Rep. 2017 Nov 21;7(1):15952. doi: 10.1038/s41598-017-16159-x.


  40. Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease
    Patel PJ1,2, Smith D3, Connor JP4, Horsfall LU1,2, Hayward KL2, Hossain F5, Williams S5, Johnson T5, Stuart KA1, Brown NN6, Saad N7, Clouston AD2, Irvine KM2,8, Russell AW9,10, Valery PC2,3,9, Powell EE1,2. Can J Gastroenterol Hepatol. 2017;2017:7927685. doi: 10.1155/2017/7927685. Epub 2017 Nov 1.


  41. Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes
    Bril F1, Kalavalapalli S2, Clark VC3, Lomonaco R1, Soldevila-Pico C3, Liu IC2, Orsak B4, Tio F5, Cusi K6. Clin Gastroenterol Hepatol. 2017 Dec 6. pii: S1542-3565(17)31424-6. doi: 10.1016/j.cgh.2017.12.001. [Epub ahead of print]


  42. A critical review of endpoints for non-cirrhotic NASH therapeutic trials
    Ratziu V1. J Hepatol. 2017 Dec 6. pii: S0168-8278(17)32481-9. doi: 10.1016/j.jhep.2017.12.001. [Epub ahead of print]


  43. The sedentary (r)evolution: Have we lost our metabolic flexibility?
    Freese J1, Klement RJ2, Ruiz-Núñez B3, Schwarz S4, Lötzerich H1. F1000Res. 2017 Oct 2;6:1787. doi: 10.12688/f1000research.12724.1. eCollection 2017.


  44. Fibromax-based nonalcoholic fatty liver disease in chronic obstructive pulmonary disease patients with obstructive sleep apnea: Methodological considerations
    Monneret D1. F1000Res. 2017 Sep 8;6:1669. doi: 10.12688/f1000research.12581.1. eCollection 2017.


  45. Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis
    Younossi ZM1, Loomba R2, Anstee QM3, Rinella ME4, Bugianesi E5, Marchesini G6, Neuschwander-Tetri BA7, Serfaty L8, Negro F9, Caldwell SH10, Ratziu V11, Corey KE12, Friedman SL13, Abdelmalek MF14, Harrison SA15, Sanyal AJ16, Lavine JE17, Mathurin P18, Charlton MR19, Goodman ZD1, Chalasani NP9,20, Kowdley KV21, George J22, Lindor K23. Hepatology. 2017 Dec 9. doi: 10.1002/hep.29721. [Epub ahead of print]


  46. Liver zonation in children with NAFLD: associations with dietary fructose and uric acid concentrations
    Nobili V1,2, Mosca A1, De Vito R3, Raponi M4, Scorletti E5, Byrne CD5,6. Liver Int. 2017 Dec 9. doi: 10.1111/liv.13661. [Epub ahead of print]


  47. Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH)
    Younossi ZM1, Loomba R2, Rinella ME3, Bugianesi E4, Marchesini G5, Neuschwander-Tetri BA6, Serfaty L7, Negro F8, Caldwell SH9, Ratziu V10, Corey KE11, Friedman SL12, Abdelmalek MF13, Harrison SA14, Sanyal AJ15, Lavine JE16, Mathurin P17, Charlton MR18, Chalasani NP19, Anstee QM20, Kowdley KV21, George J22, Goodman ZD1, Lindor K23. Hepatology. 2017 Dec 9. doi: 10.1002/hep.29724. [Epub ahead of print]


  48. Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity
    Kwak MS1, Kim D2. Korean J Intern Med. 2017 Dec 6. doi: 10.3904/kjim.2017.343. [Epub ahead of print]


  49. Association of Nonalcoholic Fatty Liver Disease With Lower Brain Volume in Healthy Middle-Aged Adults in the Framingham Study
    Weinstein G1, Zelber-Sagi S1,2, Preis SR3,4, Beiser AS3,4,5, DeCarli C6, Speliotes EK7,8, Satizabal CL4,5, Vasan RS4,5,9, Seshadri S4,5. JAMA Neurol. 2017 Nov 20. doi: 10.1001/jamaneurol.2017.3229. [Epub ahead of print]


  50. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission
    Wild SH, Walker JJ, Morling JR, McAllister DA, Colhoun HM, Farran B, McGurnaghan S, McCrimmon R, Read SH, Sattar N, Byrne CD; Scottish Diabetes Research Network Epidemiology Group. Diabetes Care. 2017 Nov 22. pii: dc171590. doi: 10.2337/dc17-1590. [Epub ahead of print]


  51. Role of imaging based biomarkers in NAFLD: Recent advances in clinical application and future research directions
    Loomba R1. J Hepatol. 2017 Dec 1. pii: S0168-8278(17)32472-8. doi: 10.1016/j.jhep.2017.11.028. [Epub ahead of print]


  52. Investigating Molecular Connections of Non-alcoholic Fatty Liver Disease with Associated Pathological Conditions in West Virginia for Biomarker Analysis
    Sharma DL1, Lakhani HV1, Klug RL2, Snoad B1, El-Hamdani R1, Shapiro JI1, Sodhi K2. J Clin Cell Immunol. 2017 Oct;8(5). pii: 523. doi: 10.4172/2155-9899.1000523. Epub 2017 Sep 29.


  53. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography
    Tsai E1, Lee TP2. Clin Liver Dis. 2018 Feb;22(1):73-92. doi: 10.1016/j.cld.2017.08.004.


  54. Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients
    Bril F1,2, Portillo-Sanchez P1, Liu IC1, Kalavalapalli S1, Dayton K3, Cusi K4,2. Diabetes Care. 2017 Nov 13. pii: dc171349. doi: 10.2337/dc17-1349. [Epub ahead of print]


  55. Text messaging approach improves weight loss in patients with nonalcoholic fatty liver disease: A randomized study
    Axley P1, Kodali S2, Kuo YF3, Ravi S1, Seay T2, Parikh NM4, Singal AK2. Liver Int. 2017 Nov 8. doi: 10.1111/liv.13622. [Epub ahead of print]


  56. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
    Manne V1, Handa P1, Kowdley KV2. Clin Liver Dis. 2018 Feb;22(1):23-37. doi: 10.1016/j.cld.2017.08.007. Epub 2017 Oct 18.


  57. Risk Factors for the Development of Nonalcoholic Fatty LiverDisease/Nonalcoholic Steatohepatitis, Including Genetics
    Lim HW1, Bernstein DE2. Clin Liver Dis. 2018 Feb;22(1):39-57. doi: 10.1016/j.cld.2017.08.008. Epub 2017 Oct 6.


  58. Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Younossi ZM1, Henry L2, Bush H3, Mishra A4. Clin Liver Dis. 2018 Feb;22(1):1-10. doi: 10.1016/j.cld.2017.08.001. Epub 2017 Oct 14.


  59. Bariatric Surgery as an Efficient Treatment for Non-Alcoholic Fatty Liver Diseasein a Prospective Study with 1-Year Follow-up : BariScan Study
    Nickel F1, Tapking C1, Benner L2, Sollors J3, Billeter AT1, Kenngott HG1, Bokhary L1, Schmid M1, von Frankenberg M1, Fischer L1, Mueller S3, Müller-Stich BP4. Obes Surg. 2017 Nov 9. doi: 10.1007/s11695-017-3012-z. [Epub ahead of print]


  60. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation
    Carter D1, Dieterich DT2, Chang C2. Clin Liver Dis. 2018 Feb;22(1):213-227. doi: 10.1016/j.cld.2017.08.015. Epub 2017 Oct 6.


  61. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
    Lonardo A1, Nascimbeni F1, Mantovani A2, Targher G3. J Hepatol. 2017 Nov 2. pii: S0168-8278(17)32335-8. doi: 10.1016/j.jhep.2017.09.021. [Epub ahead of print]


  62. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration
    Patel YA1, Gifford EJ1, Glass LM2, McNeil R1, Turner MJ1, Han B1, Provenzale D1, Choi SS1, Moylan CA1, Hunt CM1. Aliment Pharmacol Ther. 2017 Nov 8. doi: 10.1111/apt.14411. [Epub ahead of print]


  63. Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Gawrieh S1, Chalasani N2. Clin Liver Dis. 2018 Feb;22(1):189-199. doi: 10.1016/j.cld.2017.08.013. Epub 2017 Oct 10.


  64. Non-alcoholic Fatty Liver Disease in Morbidly Obese Individuals Undergoing Bariatric Surgery: Prevalence and Effect of the Pre-Bariatric Very Low Calorie Diet
    Schwenger KJP1,2, Fischer SE2,3, Jackson TD4,5, Okrainec A1,4,5, Allard JP6,7,8. Obes Surg. 2017 Nov 2. doi: 10.1007/s11695-017-2980-3. [Epub ahead of print]


  65. Nonalcoholic Fatty Liver Disease and Metabolic Syndrome
    Kim D1, Touros A1, Kim WR2. Clin Liver Dis. 2018 Feb;22(1):133-140. doi: 10.1016/j.cld.2017.08.010. Epub 2017 Oct 21.


  66. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma
    Massoud O1, Charlton M2. Clin Liver Dis. 2018 Feb;22(1):201-211. doi: 10.1016/j.cld.2017.08.014.


  67. Pharmacotherapy for NASH: Current and emerging
    Konerman MA1, Jones JC2, Harrison SA3. J Hepatol. 2017 Nov 6. pii: S0168-8278(17)32394-2. doi: 10.1016/j.jhep.2017.10.015. [Epub ahead of print]


  68. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease
    Woodhouse CA1, Patel VC1, Singanayagam A1, Shawcross DL1. Aliment Pharmacol Ther. 2017 Oct 30. doi: 10.1111/apt.14397. [Epub ahead of print]


  69. Endocrine Disruptors and Developmental Origins of Nonalcoholic Fatty Liver Disease
    Treviño LS1, Katz TA1. Endocrinology. 2017 Nov 6. doi: 10.1210/en.2017-00887. [Epub ahead of print]


  70. Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey
    Sheridan DA1, Aithal G2, Alazawi W3, Allison M4, Anstee Q5, Cobbold J6, Khan S7, Fowell A8, McPherson S9, Newsome PN10,11, Oben J12, Tomlinson J13, Tsochatzis E14. Frontline Gastroenterol. 2017 Oct;8(4):252-259. doi: 10.1136/flgastro-2017-100806. Epub 2017 Apr 28.


  71. The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View
    Lindenmeyer CC1, McCullough AJ2. Clin Liver Dis. 2018 Feb;22(1):11-21. doi: 10.1016/j.cld.2017.08.003.


  72. The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom
    Gunn NT1, Shiffman ML2. Clin Liver Dis. 2018 Feb;22(1):109-119. doi: 10.1016/j.cld.2017.08.006.


  73. Steatosis and NASH in type 2 diabetes
    Hu M1, Phan F1, Bourron O2, Ferré P1, Foufelle F3. . Biochimie. 2017 Oct 31. pii: S0300-9084(17)30271-7. doi: 10.1016/j.biochi.2017.10.019. [Epub ahead of print]


  74. Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies
    Wattacheril J1, Issa D2, Sanyal A2. Annu Rev Pharmacol Toxicol. 2017 Oct 20. doi: 10.1146/annurev-pharmtox-010617-052545. [Epub ahead of print]


  75. The Microbiome That Shapes Us: Can It Cause Obesity?
    Omer E1, Atassi H2. Curr Gastroenterol Rep. 2017 Oct 27;19(12):59. doi: 10.1007/s11894-017-0600-y.


  76. Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance
    Baratta F1,2, Pastori D1,2, Polimeni L1, Bucci T3, Ceci F4, Calabrese C1, Ernesti I5, Pannitteri G6, Violi F1, Angelico F7, Del Ben M1. Am J Gastroenterol. 2017 Oct 24. doi: 10.1038/ajg.2017.371. [Epub ahead of print]


  77. Updates on Dietary Models of Non-Alcoholic Fatty Liver Disease: Current Studies and Insights
    Stephenson K1, Kennedy L2, Hargrove L3, Demieville J2, Thomson J2, Alpini G2, Francis H2. Gene Expr. 2017 Nov 2. doi: 10.3727/105221617X15093707969658. [Epub ahead of print]


  78. Non-invasive diagnosis of non-alcoholic fatty liver disease (NAFLD) using ultrasound image echogenicity
    Benjamin A, Zubajlo R, Thomenius K, Dhyani M, Kaliannan K, Samir AE, Anthony BW. Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:2920-2923. doi: 10.1109/EMBC.2017.8037468.


  79. Impact of bariatric surgery on outcomes of patients with nonalcoholic fatty liverdisease: a nationwide inpatient sample analysis, 2004-2012
    McCarty TR1, Echouffo-Tcheugui JB2, Lange A1, Haque L1, Njei B3. Surg Obes Relat Dis. 2017 Sep 14. pii: S1550-7289(17)30919-X. doi: 10.1016/j.soard.2017.09.511. [Epub ahead of print]


  80. Benefit-risk of intraoperative liver biopsy during bariatric surgery: review and perspectives
    Barbois S1, Arvieux C2, Leroy V3, Reche F2, Stürm N4, Borel AL5. Surg Obes Relat Dis. 2017 Oct;13(10):1780-1786. doi: 10.1016/j.soard.2017.07.032. Epub 2017 Aug 14.


  81. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Golabi P1, Bush H1, Younossi ZM2. Clin Liver Dis. 2017 Nov;21(4):739-753. doi: 10.1016/j.cld.2017.06.010. Epub 2017 Jul 29.


  82. Diagnostic Accuracy of Magnetic Resonance Imaging Hepatic Proton Density Fat Fraction in Pediatric Nonalcoholic Fatty Liver Disease
    Middleton MS1, Van Natta ML2, Heba ER1, Alazraki A3, Trout AT4, Masand P5, Brunt EM6, Kleiner DE7, Doo E8, Tonascia J2, Lavine JE9, Shen W9, Hamilton G1, Schwimmer JB10, Sirlin CB1; NASH Clinical Research Network. Hepatology. 2017 Oct 13. doi: 10.1002/hep.29596. [Epub ahead of print]


  83. Challenges in Screening for Pediatric Nonalcoholic Fatty Liver Disease
    Ferguson AE1, Xanthakos SA1, Siegel RM1. Clin Pediatr (Phila). 2017 Oct 1:9922817733300. doi: 10.1177/0009922817733300. [Epub ahead of print]


  84. Noninvasive Testing for Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Patients With Psoriasis Receiving Long-term Methotrexate Sodium Therapy
    Bauer B1, Chyou PH2, Stratman EJ3, Green C3. JAMA Dermatol. 2017 Aug 23. doi: 10.1001/jamadermatol.2017.2083. [Epub ahead of print]


  85. The Association of Inflammatory Markers With Nonalcoholic Fatty Liver Disease Differs by Human Immunodeficiency Virus Serostatus
    Price JC1, Wang R2, Seaberg EC2, Budoff MJ3, Kingsley LA4, Palella FJ5, Witt MD6, Post WS3, Thio CL7. Open Forum Infect Dis. 2017 Jul 23;4(3):ofx153. doi: 10.1093/ofid/ofx153. eCollection 2017 Summer.


  86. Developmental Programming of Obesity and Liver Metabolism by Maternal Perinatal Nutrition Involves the Melanocortin System
    Cordero P1, Li J2, Nguyen V3, Pombo J4, Maicas N5, Novelli M6, Taylor PD7, Samuelsson AM8, Vinciguerra M9,10, Oben JA11,12. Nutrients. 2017 Sep 20;9(9). pii: E1041. doi: 10.3390/nu9091041.


  87. Histopathology, grading and staging of nonalcoholic fatty liver disease
    Kleiner D1. Minerva Gastroenterol Dietol. 2017 Sep 25. doi: 10.23736/S1121-421X.17.02445-X. [Epub ahead of print]


  88. Performance of fibrosis prediction scores in paediatric non-alcoholic fatty liver disease
    Jackson JA1, Konomi JV2, Mendoza MV2, Krasinskas A3, Jin R2, Caltharp S3, Mouzaki M4, Vos MB2. J Paediatr Child Health. 2017 Sep 25. doi: 10.1111/jpc.13689. [Epub ahead of print]


  89. Coffee consumption is not associated with prevalent subclinical cardiovascular disease (CVD) or the risk of CVD events, in nonalcoholic fatty liver disease: results from the multi-ethnic study of atherosclerosis
    Simon TG1, Trejo MEP2, Zeb I3, Frazier-Wood AC4, McClelland RL2, Chung RT1, Budoff MJ5. Metabolism. 2017 Oct;75:1-5. doi: 10.1016/j.metabol.2017.06.007. Epub 2017 Jun 24.


  90. Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals
    Della Pepa G1, Vetrani C2, Lombardi G3, Bozzetto L4, Annuzzi G5, Rivellese AA6. Nutrients. 2017 Sep 26;9(10). pii: E1065. doi: 10.3390/nu9101065.


  91. Rising Rates of Hepatocellular Carcinoma Leading to Liver Transplantation in Baby Boomer Generation with Chronic Hepatitis C, Alcohol Liver Disease, and Nonalcoholic Steatohepatitis-Related Liver Disease
    Cholankeril G1, Yoo ER2, Perumpail RB3, Liu A4, Sandhu JS5, Nair S6, Hu M7, Ahmed A8. Diseases. 2017 Sep 26;5(4). pii: E20. doi: 10.3390/diseases5040020.


  92. Bile acid alterations are associated with insulin resistance, but not with NASH in obese subjects
    Legry V1, Francque S2,3, Haas JT1, Verrijken A3,4, Caron S1, Chávez-Talavera O1, Vallez E1, Vonghia L2,3, Dirinck E4, Verhaegen A4, Kouach M5, Lestavel S1, Lefebvre P1, Van Gaal L3,4, Tailleux A1, Paumelle R1, Staels B1. J Clin Endocrinol Metab. 2017 Aug 4. doi: 10.1210/jc.2017-01397. [Epub ahead of print]


  93. Energy-matched moderate and high intensity exercise training improves nonalcoholic fatty liver disease risk independent of changes in body mass or abdominal adiposity - a randomized trial
    Winn NC1, Ying L1, Rector RS2, Parks EJ1, Ibdah JA3, Kanaley JA4. Metabolism. 2017 Sep 20. pii: S0026-0495(17)30228-7. doi: 10.1016/j.metabol.2017.08.012. [Epub ahead of print]


  94. Nonalcoholic Fatty Liver Disease Incidence and Impact on Metabolic Burden and Death: a 20 Year-Community Study
    Allen AM1, Terry TM2, Larson JJ2, Coward A1, Somers VK3, Kamath PS1. Hepatology. 2017 Sep 23. doi: 10.1002/hep.29546. [Epub ahead of print]


  95. Fatty liver without a large
    Yousef MH1, Al Juboori A1, Albarrak AA1, Ibdah JA1, Tahan V1. World J Gastrointest Pathophysiol. 2017 Aug 15;8(3):100-107. doi: 10.4291/wjgp.v8.i3.100.


  96. Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases
    Samuel VT1, Shulman GI2. Cell Metab. 2017 Aug 29. pii: S1550-4131(17)30487-4. doi: 10.1016/j.cmet.2017.08.002. [Epub ahead of print]


  97. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
    Younossi Z1,2, Anstee QM3,4, Marietti M5, Hardy T3,4, Henry L1,2, Eslam M6, George J6, Bugianesi E5. Nat Rev Gastroenterol Hepatol. 2017 Sep 20. doi: 10.1038/nrgastro.2017.109. [Epub ahead of print]


  98. Rising Rate of Liver Transplantation in the Baby Boomer Generation with Non-alcoholic Steatohepatitis in the United States
    Siddique O1, Joseph-Talreja M2, Yoo ER3, Perumpail RB2, Cholankeril G4, Harrison SA5, Younossi ZM6, Wong RJ7, Ahmed A2. J Clin Transl Hepatol. 2017 Sep 28;5(3):193-196. doi: 10.14218/JCTH.2017.00003. Epub 2017 Jun 3.


  99. Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease
    Cheah MC1, McCullough AJ2,3, Goh GB1,4. J Clin Transl Hepatol. 2017 Sep 28;5(3):261-271. doi: 10.14218/JCTH.2017.00009. Epub 2017 Jun 24.


  100. Mediterranean Diet and Multi-Ingredient-Based Interventions for the Management of Non-Alcoholic Fatty Liver Disease
    Suárez M1, Boqué N2, Del Bas JM3, Mayneris-Perxachs J4, Arola L5,6, Caimari A7. Nutrients. 2017 Sep 22;9(10). pii: E1052. doi: 10.3390/nu9101052.


  101. Reversal of fibrosis in patients with nonalcoholic steatohepatosis after gastric bypass surgery
    Parker BM1,2, Wu J3, You J4, Barnes DS5, Yerian L6, Kirwan JP7, Schauer PR8, Sessler DI9. BMC Obes. 2017 Sep 12;4:32. doi: 10.1186/s40608-017-0168-y. eCollection 2017.


  102. Nuclear lamina genetic variants, including a truncated LAP2, in twins and siblings with nonalcoholic fatty liver disease
    Brady GF1, Kwan R1, Ulintz PJ2, Nguyen P3, Bassirian S3, Basrur V2, Nesvizhskii AI2,4, Loomba R3, Omary MB1. Hepatology. 2017 Sep 13. doi: 10.1002/hep.29522. [Epub ahead of print]


  103. Can Diet Help Non-Obese Individuals with Non-Alcoholic Fatty Liver Disease (NAFLD)?
    Merchant HA1. J Clin Med. 2017 Sep 19;6(9). pii: E88. doi: 10.3390/jcm6090088.


  104. The ASK1 Inhibitor Selonsertib in Patients with Nonalcoholic Steatohepatitis: A Randomized, Phase 2 Trial
    Loomba R1, Lawitz E2, Mantry PS3, Jayakumar S4, Caldwell SH5, Arnold H6, Diehl AM7, Djedjos CS8, Han L8, Myers RP8, Subramanian GM8, McHutchison JG8, Goodman ZD9, Afdhal NH10, Charlton MR11; GS-US-384-1497 Investigators. Hepatology. 2017 Sep 11. doi: 10.1002/hep.29514. [Epub ahead of print]


  105. Impact of body mass index in liver transplantation for nonalcoholic fatty liverdisease and alcoholic liver disease
    O'Neill S1, Napetti S1, Cornateanu S1, Sutherland AI1, Wigmore S1, Oniscu GC1, Adair A2. HPB (Oxford). 2017 Sep 7. pii: S1365-182X(17)30873-0. doi: 10.1016/j.hpb.2017.08.003. [Epub ahead of print]


  106. Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease
    Shetty A1, Cho W1, Alazawi W2, Syn WK3. Am J Med Sci. 2017 Aug;354(2):172-181. doi: 10.1016/j.amjms.2017.03.014. Epub 2017 Mar 14.


  107. Obstetric Outcomes in Women with Nonalcoholic Fatty Liver Disease
    Lee YW1, Yarrington CD2. Metab Syndr Relat Disord. 2017 Aug 28. doi: 10.1089/met.2017.0058. [Epub ahead of print]


  108. Alcohol and Obesity: A Dangerous Association for Fatty Liver Disease
    Mahli A1, Hellerbrand C. Dig Dis. 2016;34 Suppl 1:32-9. doi: 10.1159/000447279. Epub 2016 Aug 22.


  109. Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease
    Lee HW1, Park SY2, Kim SU1, Jang JY3, Park H4, Kim JK1, Lee CK5, Chon YE1, Han KH1. PLoS One. 2016 Jun 10;11(6):e0157358. doi: 10.1371/journal.pone.0157358. eCollection 2016.


  110. Formulation for Effective Screening and Management of Nonalcoholic Steatohepatitis: Noninvasive NAFLD Management Strategy
    Hirose K1, Kanefuji T2, Suda T2, Sugitani S3, Nagasaki K4, Kubota T5, Igarashi M1, Terai S1. Gastroenterol Res Pract. 2016;2016:6343656. doi: 10.1155/2016/6343656. Epub 2016 Jun 13.


  111. The impact of body weight gain on nonalcoholic fatty liver disease and metabolic syndrome during earlier and later adulthood
    Du S1, Wang C2, Jiang W3, Li C4, Li Y1, Feng R5, Sun C6. Diabetes Res Clin Pract. 2016 Jun;116:183-91. doi: 10.1016/j.diabres.2016.04.047. Epub 2016 Apr 30.


  112. The Association between Non-Invasive Hepatic Fibrosis Markers and Cardiometabolic Risk Factors in the Framingham Heart Study
    Long MT1,2, Pedley A2,3, Massaro JM2,4, Hoffmann U5, Fox CS2,6. PLoS One. 2016 Jun 24;11(6):e0157517. doi: 10.1371/journal.pone.0157517. eCollection 2016.


  113. Nonalcoholic fatty liver disease and obstructive sleep apnea
    Aron-Wisnewsky J1, Clement K2, Pépin JL3. Metabolism. 2016 Aug;65(8):1124-35. doi: 10.1016/j.metabol.2016.05.004. Epub 2016 May 13.


  114. Host factors are dominant in the development of post-liver transplant non-alcoholic steatohepatitis
    Boga S1, Munoz-Abraham AS1, Rodriguez-Davalos MI1, Emre SH1, Jain D1, Schilsky ML1. World J Hepatol. 2016 May 28;8(15):659-64. doi: 10.4254/wjh.v8.i15.659.


  115. Non-alcoholic fatty liver disease and dyslipidemia: An update
    Katsiki N1, Mikhailidis DP2, Mantzoros CS3.Author information Metabolism. 2016 May 13. pii: S0026-0495(16)30018-X. doi: 10.1016/j.metabol.2016.05.003. [Epub ahead of print]


  116. The Natural Course of Non-Alcoholic Fatty Liver Disease
    Calzadilla Bertot L1, Adams LA2,3. Int J Mol Sci. 2016 May 20;17(5). pii: E774. doi: 10.3390/ijms17050774.


  117. Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease
    Hannah WN Jr1, Harrison SA2. Dig Dis Sci. 2016 May;61(5):1365-74. doi: 10.1007/s10620-016-4153-y.


  118. Gut Microbiota and Lifestyle Interventions in NAFLD
    Houghton D1, Stewart CJ2, Day CP3,4, Trenell M5. Int J Mol Sci. 2016 Mar 25;17(4). pii: E447. doi: 10.3390/ijms17040447.


  119. A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD
    Hossain N1, Kanwar P1, Mohanty SR1. Gastroenterol Res Pract. 2016;2016:7109270. doi: 10.1155/2016/7109270. Epub 2016 Feb 23.


  120. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016
    Kaswala DH1, Lai M1, Afdhal NH2. Dig Dis Sci. 2016 May;61(5):1356-64. doi: 10.1007/s10620-016-4079-4. Epub 2016 Mar 26.


  121. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection-Liver: The
    Ballestri S1, Nascimbeni F2,3, Romagnoli D4, Baldelli E5, Targher G6, Lonardo A7. Int J Mol Sci. 2016 Mar 9;17(3). pii: E355. doi: 10.3390/ijms17030355.


  122. Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease
    Bedossa P1, Patel K2. Gastroenterology. 2016 Mar 19. pii: S0016-5085(16)00354-1. doi: 10.1053/j.gastro.2016.03.008. [Epub ahead of print]


  123. Telomeres, NAFLD and Chronic Liver Disease
    Donati B1, Valenti L2. Int J Mol Sci. 2016 Mar 15;17(3). pii: E383. doi: 10.3390/ijms17030383.


  124. Non-alcoholic fatty liver disease and liver transplantation
    Khan RS1, Newsome PN2. Metabolism. 2016 Mar 3. pii: S0026-0495(16)00052-4. doi: 10.1016/j.metabol.2016.02.013. [Epub ahead of print]


  125. Perspectives on Treatment for Nonalcoholic Steatohepatitis
    Lassailly G1, Caiazzo R2, Pattou F2, Mathurin P3. Gastroenterology. 2016 Mar 10. pii: S0016-5085(16)00323-1. doi: 10.1053/j.gastro.2016.03.004. [Epub ahead of print]


  126. Comparison of Doppler ultrasound and transient elastography in the diagnosis of significant fibrosis in patients with nonalcoholic steatohepatitis
    Ergelen R1, Yilmaz Y2, Asedov R3, Celikel C4, Akin H2, Bugdayci O3, Altun E5, Tuney D3. Abdom Radiol (NY). 2016 Mar 10. [Epub ahead of print]


  127. Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes
    Lomonaco R1, Bril F2, Portillo-Sanchez P2, Ortiz-Lopez C3, Orsak B3, Biernacki D2, Lo M4, Suman A5, Weber MH6, Cusi K7. Diabetes Care. 2016 Feb 9. pii: dc151876. [Epub ahead of print]


  128. Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score
    Tapper EB1, Hunink MG2,3, Afdhal NH1, Lai M1, Sengupta N4. PLoS One. 2016 Feb 23;11(2):e0147237. doi: 10.1371/journal.pone.0147237. eCollection 2016.


  129. Histamine H2-Receptor Antagonist Use Is Associated With Lower Prevalence of Nonalcoholic Fatty Liver Disease: A Population-based Study From the National Health and Nutrition Examination Survey, 2001-2006
    Shen H1, Liangpunsakul S. J Clin Gastroenterol. 2016 Feb 22. [Epub ahead of print]


  130. Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease
    Jiang ZG1, Tapper EB1, Connelly MA2, Pimentel CM1, Feldbrügge L1, Kim M3, Krawczyk S3, Afdh Al N1, Robson SC1, Herman M3, Otvos JD2, Mukamal KJ4, Lai M1. Liver Int. 2016 Jan 27. doi: 10.1111/liv.13076. [Epub ahead of print]


  131. Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis
    Corey KE1,2, Klebanoff MJ3,4, Tramontano AC5, Chung RT6,7, Hur C8,9,10. Dig Dis Sci. 2016 Jan 29. [Epub ahead of print]


  132. Nonalcoholic Steatohepatitis: Diagnostic Challenges
    Gill RM1, Kakar S2. Surg Pathol Clin. 2013 Jun;6(2):227-57. doi: 10.1016/j.path.2013.03.002. Epub 2013 May 4.


  133. Is There Any Relation between the Degree of Fatty Liver Disease and Severity of Lower Urinary Tract Symptoms?
    Song YA1, Kwon SS2, Doo SW3, Kim JH4, Yang WJ3, Song YS3. Urology. 2015 Dec 9. pii: S0090-4295(15)01099-7. doi: 10.1016/j.urology.2015.11.030. [Epub ahead of print]


  134. Circulating microRNAs in nonalcoholic fatty liver disease
    DiStefano JK1, Gerhard GS2. Expert Rev Gastroenterol Hepatol. 2015 Nov 25. [Epub ahead of print]


  135. Clinical patterns of hepatocellular carcinoma (hcc) in non alcoholic fatty liver disease (NAFLD): A multicenter prospective study
    Piscaglia F1, Svegliati-Baroni G2, Barchetti A3, Pecorelli A1, Marinelli S1, Tiribelli C3,4, Bellentani S3; HCC-NAFLD Italian Study group. Hepatology. 2015 Nov 24. doi: 10.1002/hep.28368. [Epub ahead of print]


  136. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
    Armstrong MJ1, Gaunt P2, Aithal GP3, Barton D4, Hull D4, Parker R1, Hazlehurst JM5, Guo K4; LEAN trial team, Abouda G6, Aldersley MA7, Stocken D8, Gough SC5, Tomlinson JW5, Brown RM9, Hübscher SG10, Newsome PN11. Lancet. 2015 Nov 19. pii: S0140-6736(15)00803-X. doi: 10.1016/S0140-6736(15)00803-X. [Epub ahead of print]


  137. Non-alcoholic fatty liver disease and risk of cardiovascular disease
    Lonardo A1, Sookoian S2, Pirola CJ3, Targher G4. Metabolism. 2015 Sep 25. pii: S0026-0495(15)00271-1. doi: 10.1016/j.metabol.2015.09.017. [Epub ahead of print]


  138. Dietary approach in the treatment of nonalcoholic fatty liver disease
    Ferolla SM1, Silva LC1, Ferrari Mde L1, da Cunha AS1, Martins Fdos S1, Couto CA1, Ferrari TC1. World J Hepatol. 2015 Oct 28;7(24):2522-34. doi: 10.4254/wjh.v7.i24.2522.


  139. The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis
    Anderson EL1, Howe LD1, Jones HE2, Higgins JP3, Lawlor DA1, Fraser A1. PLoS One. 2015 Oct 29;10(10):e0140908. doi: 10.1371/journal.pone.0140908. eCollection 2015.


  140. Non-alcoholic Steatohepatitis is Associated with Increased Mortality in Obese Patients Undergoing Bariatric Surgery
    Goossens N1, Hoshida Y2, Song WM3, Jung M4, Morel P4, Nakagawa S5, Zhang B3, Frossard JL6, Spahr L6, Friedman SL5, Negro F7, Rubbia-Brandt L8, Giostra E6. Clin Gastroenterol Hepatol. 2015 Oct 19. pii: S1542-3565(15)01406-8. doi: 10.1016/j.cgh.2015.10.010. [Epub ahead of print]


  141. Nonalcoholic Steatohepatitis is the Most Rapidly Growing Indication for Simultaneous Liver Kidney Transplantation in the United States
    Singal AK1, Hasanin M, Kaif M, Wiesner R, Kuo YF. Transplantation. 2015 Oct 16. [Epub ahead of print]


  142. Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD
    Nobili V1, Alisi A2, Musso G3, Scorletti E4,5, Calder PC4,5, Byrne CD4,5. Crit Rev Clin Lab Sci. 2015 Oct 14:1-15. [Epub ahead of print]


  143. Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease
    Wood KL1, Miller MH2, Dillon JF2. BMJ Open Gastroenterol. 2015 Feb 17;2(1):e000019. doi: 10.1136/bmjgast-2014-000019. eCollection 2015.


  144. Sex-specific differences in hepatic fat oxidation and synthesis may explain the higher propensity for NAFLD in men
    Pramfalk C1, Pavlides M2,3, Banerjee R2, McNeil CA1, Neubauer S2, Karpe F1,4, Hodson L1. J Clin Endocrinol Metab. 2015 Sep 28:jc20152649. [Epub ahead of print]


  145. Hype or Reality: Should Patients with Metabolic Syndrome-related NAFLD be on the Hunter-Gatherer (Paleo) Diet to Decrease Morbidity?
    Tarantino G1, Citro V2, Finelli C3. J Gastrointestin Liver Dis. 2015 Sep;24(3):359-68. doi: 10.15403/jgld.2014.1121.243.gta.


  146. Nonalcoholic fatty liver disease: Current status and future directions
    Demir M1, Lang S1, Steffen HM1. J Dig Dis. 2015 Sep 25. doi: 10.1111/1751-2980.12291. [Epub ahead of print]


  147. Nonalcoholic Fatty Liver Disease and Fibrosis in Youth Taking Psychotropic Medications: Literature Review, Case Reports, and Management
    Gracious BL1,2, Bhatt R2,3, Potter C4. J Child Adolesc Psychopharmacol. 2015 Oct 8. [Epub ahead of print]


  148. Relevance of low testosterone to non-alcoholic fatty liver disease
    Mody A1, White D2, Kanwal F3, Garcia JM4. Cardiovasc Endocrinol. 2015 Sep 1;4(3):83-89.


  149. The Gut Microbiota and Nonalcoholic Fatty Liver Disease
    Quigley EM1, Monsour HP1. Semin Liver Dis. 2015 Aug;35(3):262-9. doi: 10.1055/s-0035-1562946. Epub 2015 Sep 17.


  150. Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander
    Vanni E1, Marengo A1, Mezzabotta L1, Bugianesi E1. Semin Liver Dis. 2015 Aug;35(3):236-49. doi: 10.1055/s-0035-1562944. Epub 2015 Sep 17.


  151. Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability
    Luther J1, Garber JJ1, Khalili H1, Dave M2, Bale SS3, Jindal R3, Motola DL1, Luther S1, Bohr S3, Jeoung SW1, Deshpande V1, Singh G4, Turner JR4, Yarmush ML3, Chung RT1, Patel SJ3. Cell Mol Gastroenterol Hepatol. 2015 Mar;1(2):222-232.


  152. Relevance of low testosterone to non-alcoholic fatty liver disease
    Mody A1, White D2, Kanwal F3, Garcia JM4. Cardiovasc Endocrinol. 2015 Sep 1;4(3):83-89.


  153. The Gut Microbiota and Nonalcoholic Fatty Liver Disease
    Quigley EM1, Monsour HP1. Semin Liver Dis. 2015 Aug;35(3):262-9. doi: 10.1055/s-0035-1562946. Epub 2015 Sep 17.


  154. Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander
    Vanni E1, Marengo A1, Mezzabotta L1, Bugianesi E1. Semin Liver Dis. 2015 Aug;35(3):236-49. doi: 10.1055/s-0035-1562944. Epub 2015 Sep 17.


  155. Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability
    Luther J1, Garber JJ1, Khalili H1, Dave M2, Bale SS3, Jindal R3, Motola DL1, Luther S1, Bohr S3, Jeoung SW1, Deshpande V1, Singh G4, Turner JR4, Yarmush ML3, Chung RT1, Patel SJ3. Cell Mol Gastroenterol Hepatol. 2015 Mar;1(2):222-232.


  156. The Prevalence and Presumed Etiology of Elevated Aminotransferase Levels in a Pacific Northwest Tribal Community
    Scott J, Kowdley KV, Ioannou GN, Krantz E, Lallemand O, Tsosie U, Buchwald D. J Health Care Poor Underserved. 2015;26(3):957-66. doi: 10.1353/hpu.2015.0091.


  157. Burden of nonalcoholic fatty liver disease and advanced fibrosis in a Texas Hispanic community cohort
    Pan JJ1, Fisher-Hoch SP1, Chen C1, Feldstein AE1, McCormick JB1, Rahbar MH1, Beretta L1, Fallon MB1. World J Hepatol. 2015 Jun 18;7(11):1586-94. doi: 10.4254/wjh.v7.i11.1586.


  158. Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty Liver Disease
    Pacana T1, Cazanave S1, Verdianelli A1, Patel V1, Min HK1, Mirshahi F1, Quinlivan E2, Sanyal AJ1. PLoS One. 2015 Aug 31;10(8):e0136822. doi: 10.1371/journal.pone.0136822. eCollection 2015.


  159. Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography
    Tapper EB1, Sengupta N1, Hunink MG2,3, Afdhal NH1, Lai M1. Am J Gastroenterol. 2015 Sep;110(9):1298-304. doi: 10.1038/ajg.2015.241. Epub 2015 Aug 25.


  160. Nonmedicinal interventions in nonalcoholic fatty liver disease
    Neuman MG, Nanau RM, Cohen LB. Can J Gastroenterol Hepatol. 2015 Jun-Jul;29(5):241-52.


  161. Non-alcoholic fatty liver disease following liver transplantation: a clinical review
    Merola J1, Liapakis A2, Mulligan DC1, Yoo PS1. Clin Transplant. 2015 Sep;29(9):728-37. doi: 10.1111/ctr.12585. Epub 2015 Aug 11.


  162. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials
    Sato K1, Gosho M2, Yamamoto T3, Kobayashi Y3, Ishii N3, Ohashi T3, Nakade Y3, Ito K3, Fukuzawa Y3, Yoneda M3. Nutrition. 2015 Jul-Aug;31(7-8):923-30. doi: 10.1016/j.nut.2014.11.018. Epub 2014 Dec 24.


  163. Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
    Buzzetti E1, Lombardi R1, De Luca L1, Tsochatzis EA1. Int J Endocrinol. 2015;2015:343828. doi: 10.1155/2015/343828. Epub 2015 Apr 30.


  164. Bile Acid Signaling: Mechanism for Bariatric Surgery, Cure for NASH?
    Kohli R1, Myronovych A, Tan BK, Salazar-Gonzalez RM, Miles L, Zhang W, Oehrle M, Sandoval DA, Ryan KK, Seeley RJ, Setchell KD. Dig Dis. 2015;33(3):440-6. doi: 10.1159/000371699. Epub 2015 May 27.


  165. Trends in the Burden of Non-alcoholic Fatty Liver Disease in a US Cohort of Veterans
    Kanwal F1, Kramer JR2, Duan Z2, Yu X3, White D4, El-Serag HB5. Clin Gastroenterol Hepatol. 2015 Aug 17. pii: S1542-3565(15)01109-X. doi: 10.1016/j.cgh.2015.08.010. [Epub ahead of print]


  166. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB1, Wong RJ, Ahmed A, Harrison SA.

    Dig Dis Sci. 2015 Aug 7. [Epub ahead of print]


  167. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
    Vilar-Gomez E1, Martinez-Perez Y2, Calzadilla-Bertot L2, Torres-Gonzalez A2, Gra-Oramas B3, Gonzalez-Fabian L3, Friedman SL4, Diago M5, Romero-Gomez M6.

    Gastroenterology. 2015 Aug;149(2):367-378.e5. doi: 10.1053/j.gastro.2015.04.005. Epub 2015 Apr 10.


  168. Association of Non-alcoholic Fatty Liver Disease (NAFLD) with Hepatocellular Carcinoma (HCC) in the United States from 2004-2009
    Younossi ZM1,2,3, Otgonsuren M3, Henry L1,3, Venkatesan C2, Mishra A1, Erario M2, Hunt S1. Hepatology. 2015 Aug 14. doi: 10.1002/hep.28123. [Epub ahead of print]


  169. NAFLD Review: Diagnosis, Treatment and Outcomes
    Ahmed A1, Wong RJ2, Harrison SA3. Clin Gastroenterol Hepatol. 2015 Jul 27. pii: S1542-3565(15)00988-X. doi: 10.1016/j.cgh.2015.07.029. [Epub ahead of print]


 
 
                               
 
HBV
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
 
HE
Webcasts
Slide Library
Abstract Library
 
NASH
Webcasts
Slide Library
Abstract Library
 
 
PBC
Webcasts
Slide Library
Abstract Library
 
 
OTHER
Webcasts
Slide Library
   
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Sponsors & Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Hepatology
Substance Use Disorder
             
CLDF Follow Us
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2018 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.